Simplify & Digitize approval to conduct Bio-Equivalence and Bio-Availability study
Reform ID		F268
Description		The application process for conducting BE and BA studies was manual, time-consuming, and involved multiple layers of approvals, causing delays for pharmaceutical companies. The absence of a digital workflow reduced transparency and increased administrative burden.
Department		Drug Regulatory Authority of Pakistan - DRAP
Jurisdiction / Location		Federal - Entire Pakistan
Sector		Pharmaceuticals and Healthcare
Start Date		18-08-2025
Target Deadline		19-11-2025
Date Enacted
Implementation Status		In Progress
Progress		50%
CCORR Direction		Simplify & Digitize
Cost Savings PKR (Mil.)
Evidence